Optimisation of antiepileptic drug therapy - The importance of serum drug concentration monitoring

被引:35
作者
Yukawa, E
机构
[1] Division of Pharmaceutical Sciences, Graduate School, Kyushu University, Higashi-Ku, Fukuoka
[2] Division of Pharmaceutical Sciences, Graduate School, Kyushu University, Higashi-Ku, Fukuoka 812
关键词
D O I
10.2165/00003088-199631020-00004
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The ability to measure the serum concentrations of antiepileptic drugs, and the widespread use of this procedure, has markedly improved the treatment given to patients with epilepsy during the past 3 decades. The monitoring of antiepileptic drug concentrations in serum is necessary for the optimal drug therapy of seizures, because the therapeutic and toxic effects of these drugs are better related to serum concentration than to administered dosage. Monitoring appeared to have a major impact on improving the effectiveness and safety of antiepileptic drug therapy. The age-related variability of pharmacokinetic parameters may also require the individualisation of therapy, with subsequent re-evaluation as the person grows older. Monitoring serum concentrations of antiepileptic drugs may help to optimise the dose. A drug concentration, however, can only be regarded as a guide around which to alter the dosage according to the patient's clinical condition. Serum drug concentration monitoring is particularly useful to ensure compliance and in helping to manage combinations of antiepileptic drugs that invariably interact. The addition or deletion of other antiepileptic drugs may change dosage requirements. Therefore, routine monitoring of antiepileptic drug serum concentrations would be extremely useful, especially in the paediatric population, and in patients who require associated antiepileptic medication.
引用
收藏
页码:120 / 130
页数:11
相关论文
共 101 条
[1]   CARBAMAZEPINE DRUG-INTERACTIONS [J].
BACIEWICZ, AM .
THERAPEUTIC DRUG MONITORING, 1986, 8 (03) :305-317
[2]   CARBAMAZEPINE PLASMA-LEVELS IN CHILDREN AND ADULTS - INFLUENCE OF AGE, DOSE, AND ASSOCIATED THERAPY [J].
BATTINO, D ;
BOSSI, L ;
CROCI, D ;
FRANCESCHETTI, S ;
GOMENI, C ;
MOISE, A ;
VITALI, A .
THERAPEUTIC DRUG MONITORING, 1980, 2 (04) :315-322
[3]   CLINICAL PHARMACOKINETICS OF ANTIEPILEPTIC DRUGS IN PEDIATRIC-PATIENTS .2. PHENYTOIN, CARBAMAZEPINE, SULTHIAME, LAMOTRIGINE, VIGABATRIN, OXCARBAZEPINE AND FELBAMATE [J].
BATTINO, D ;
ESTIENNE, M ;
AVANZINI, G .
CLINICAL PHARMACOKINETICS, 1995, 29 (05) :341-369
[4]   CLINICAL PHARMACOKINETICS OF ANTIEPILEPTIC DRUGS IN PEDIATRIC-PATIENTS .1. PHENOBARBITAL, PRIMIDONE, VALPROIC ACID, ETHOSUXIMIDE AND MESUXIMIDE [J].
BATTINO, D ;
ESTIENNE, M ;
AVANZINI, G .
CLINICAL PHARMACOKINETICS, 1995, 29 (04) :257-286
[5]   PHENYTOIN MICHAELIS-MENTEN PHARMACOKINETICS IN CAUCASIAN PEDIATRIC-PATIENTS [J].
BAUER, LA ;
BLOUIN, RA .
CLINICAL PHARMACOKINETICS, 1983, 8 (06) :545-549
[6]  
BAUER LA, 1982, CLIN PHARMACOL THER, V31, P741, DOI 10.1038/clpt.1982.104
[7]   PHARMACOKINETICS - TIME-DEPENDENT CHANGES - AUTOINDUCTION OF CARBAMAZEPINE EPOXIDATION [J].
BERTILSSON, L ;
TOMSON, T ;
TYBRING, G .
JOURNAL OF CLINICAL PHARMACOLOGY, 1986, 26 (06) :459-462
[8]   CLINICAL PHARMACOKINETICS OF CARBAMAZEPINE [J].
BERTILSSON, L .
CLINICAL PHARMACOKINETICS, 1978, 3 (02) :128-143
[9]  
BOCHNER F, 1973, CLIN PHARMACOL THER, V14, P791
[10]   VALPROIC ACID DOSAGE AND PLASMA-PROTEIN BINDING AND CLEARANCE [J].
BOWDLE, TA ;
PATEL, IH ;
LEVY, RH ;
WILENSKY, AJ .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1980, 28 (04) :486-492